news aktuell GmbHnews aktuell GmbH

Grünenthal Group: Grünenthal acquires Mestex AG and its Phase-III-ready investigational medicine MTX-071 for the treatment of pain associated with osteoarthritis of the knee

Share
  • With the acquisition of Mestex AG, Grünenthal secures global rights for an attractive late-stage asset that could offer an innovative therapy option for millions of patients affected by pain related to osteoarthritis of the knee.
  • MTX-071 (resiniferatoxin) is a highly potent Transient Receptor Potential Vanilloid 1 (TRPV1) agonist. Its administration can reversibly defunctionalise TRPV1-expressing nociceptors. This can result in long lasting pain relief.

 

(Aachen, Germany) –Today, Grünenthal has announced the acquisition of Mestex AG through the takeover of all of its shares and options. Mestex AG is a Swiss biotech company that has developed the innovative investigational medicine MTX-071 (resiniferatoxin) for the intra-articular treatment of pain associated with osteoarthritis of the knee. The investigational medicine is currently concluding Phase II of clinical development and is about to enter Phase III. Initial data showed a long-lasting and significant analgesic effect and functional improvements compared to placebo (saline injection), as well as a favourable safety profile.

“Osteoarthritis is a progressive condition that currently cannot be cured.The inflamed, swollen and painful joints lead to limitation on mobility of the affected patients and may impact their quality of life significantly. Millions of patients currently receive intra-articular corticosteroids or need to undergo knee replacement surgery as last remaining treatment option,” says Jan Adams, MD, Chief Scientific Officer Grünenthal. “With MTX-071, we aim to provide these patients with a well tolerable, non-opioid therapy option that provides long-lasting pain relief and functional improvement of the affected joints.”

Grünenthal is currently preparing two pivotal Phase III studies to investigate the efficacy, safety and tolerability of MTX-071 in patients with pain associated with osteoarthritis of the knee. The studies will start in 2021 and they are part of a global development programme aimed at meeting the requirements for approval in the EU, the US, Japan and China. The mechanism of action is well validated by clinical studies with other TRPV1 agonists.

“Through the acquisition of Mestex, Grünenthal is well positioned to tap into the global osteoarthritis market. Over 50 million people are affected by osteoarthritis of the knee across the US and the EU.” says Gabriel Baertschi, Chief Executive Officer Grünenthal. “We are confident in the mechanism of action of MTX-071 and will explore its potential for the treatment of osteoarthritis related pain in additional joints.”

This acquisition will further strengthen Grünenthal’s pain-focused late-stage pipeline. The company recently announced a Phase III trial that studies the efficacy, safety and tolerability of QUTENZA® (capsaicin) 8% topical system in post-surgical neuropathic pain (PSNP) with the goal of expanding the current US label.

About MTX-071

MTX-071 is an intra-articular injection of resiniferatoxin for the treatment of pain in patients with advanced knee osteoarthritis. Resiniferatoxin is a highly potent Transient Receptor Potential Vanilloid 1 (TRPV1) agonist. Its administration can reversibly defunctionalise TRPV1-expressing nociceptors. This can result in long lasting pain relief. The investigational medicine is currently concluding Phase II and about to enter Phase III. Data shows a long-lasting and significant analgesic effect and functional improvements compared to placebo (saline injection), as well as a favourable safety profile.


About Osteoarthritis

Osteoarthritis (OA) can be defined as a group of distinct, but overlapping diseases. They may have different etiologies, but similar biological, morphological, and clinical outcomes that affect the articular cartilage, subchondral bone, ligaments, joint capsule, synovial membrane, and periarticular muscles. OA is the most common joint disease in people aged 65 and over. Its etiology is not fully understood, although there are several related factors including female gender, genetics, metabolism, and excessive mechanical stress. The diagnosis of OA is primarily based on clinical history and physical examination. The cardinal radiographic features of OA are focal/non-uniform narrowing of the joint space in the areas subjected to the most pressure, subchondral cysts, subchondral sclerosis, and osteophytes.[1]

Osteoarthritis is a joint disease in which the tissues in the joint break down over time. Common symptoms of osteoarthritis include joint pain, stiffness and swelling, as well as changes in how the joint moves and feeling like the joint is loose or unstable. The most commonly affected joints include the hands, knees, hips, neck and lower back. Treatment of osteoarthritis usually includes exercises, maintaining a healthy weight, wearing braces to help with stability, and taking medication, if prescribed.[2] Many patients will require joint replacement surgery.



About Grünenthal

Grünenthal is a global leader in pain management and related diseases. As a science-based, privately-owned pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better – and innovation is our passion. We are focusing all of our activities and efforts on working towards our vision of a world free of pain.

Grünenthal is headquartered in Aachen, Germany, and has affiliates in 29 countries across Europe, Latin America and the US. Our products are available in more than 100 countries. In 2020, Grünenthal employed around 4,500 people and achieved sales of € 1.3 bn.



[1]ICD-11 https://icd.who.int/browse11/l-m/en#/http%3a%2f%2fid.who.int%2ficd%2fentity%2f558562409

[2]National Institute of Arthritis and Musculoskeletal and Skin Diseases; What Causes Osteoarthritis, Symptoms & More | NIAMS (nih.gov)




More information: www.grunenthal.com


Follow us on:

LinkedIn: Grunenthal Group

Instagram: grunenthal

Contacts

Fabia Kehren, Head External Communications & Editorial Management
Phone: +49 241 569-3269
Fabia.Kehren@grunenthal.com

Florian Dieckmann, Head Global Communications
Phone: +49 241 569-2555
Florian.Dieckmann@grunenthal.com

About news aktuell GmbH

news aktuell GmbH
news aktuell GmbH
Mittelweg 144
20148 Hamburg

+49 (0)40 4113-32589http://www.newsaktuell.de

As wholly owned subsidiary of dpa, news aktuell provides business and organizations with effective access to media and consumers. Via the smart tools ots and zimpel, PR content accesses all media formats, including classical print, high click-rate online portals and social networks. In addition, news aktuell publishes all its customers’ PR content on www.presseportal.de, one of the PR portals with the greatest reach in Germany. By this means, all the relevant multipliers are reached globally, from editors, via digital influencers right up to specialist bloggers and interested consumers. news aktuell has been on the market since 1989. The company, with a staff complement of more than 135, has its headquarters in Hamburg. Other offices are in Berlin, Dusseldorf, Frankfurt und Munich.

Subscribe to releases from news aktuell GmbH

Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from news aktuell GmbH

Dornbracht: Den nye blandebatteriserien CYO – et suverent statement på baderommet som del av livsstilen6.5.2021 09:00:00 CEST | Pressemelding

Iserlohn, 06.05.2021 – Autentisk, ekte og sansbart. Den nye blandebatteriserien for bad CYO oppretter en forbindelse mellom Dornbrachts designhistorie og tidsånden i dag. Med en ny tolkning av C-utløpet symboliserer det strukturelle utkastet fra Sieger Design tidløs eleganse. Dermed svarer CYO på et behov for ekthet og verdibevaring, noe som blir merkbart gjennom den ekstremt høye material-, manufaktur- og produktkvaliteten.

Path2Integrity: Digital Learning - Students exchange international views on fake news, reliable information and data protection6.5.2021 08:52:48 CEST | Pressemelding

VARNA, MUNICH, COBURG, TRIER (3.5.2021) – Students from Germany and Bulgaria recently came together on a digital platform to exchange views on the topic of Covid and Fake News. Organized by Path2Integity (P2I), a Horizon 2020 project, the meeting‘s purpose was to educate new generations to recognize the integrity and nature of processes underscoring scientific research. In P2I workshops, students are asked to compare their perspective with the perspective of others, to engage in dialogue and to find common paths for the future. Most importantly, students gain insight into the ethical and research demands of science. Depending on the action, participants explore issues like data protection, reliable information, research processes and research ethics. The digital learning platform to support this was created in 2020 (www.learning-p2i.eu). It allows participants to deepen their scientific competence via an international exchange, strengthen tolerance of ambiguity and practice a change of

Hankook Tire Europe: Hankook and girl power: W Series starts on Hankook tyres at Formula 1 race weekends5.5.2021 15:44:58 CEST | Press release

Hankook is once again the exclusive tyre partner of the W Series in 2021, which this season shares the bill with the Formula 1 World Championship. This marks a world first for the premium tyre maker’s high-end Ventus Race tyre: for the first time in the history of motorsport, a single-seater racing series featuring only women drivers will support the pinnacle of motor racing.

4ARTechnologies: Market Leader in Art Security and Digitization Develops the World's First Secure NFT for Physical and Digital Artworks5.5.2021 09:00:00 CEST | Press release

(Zug, Switzerland): 4ARTechnologies, the market leader in art security and digitization announces the next sensation: "We give art creators and collectors the exclusive opportunity to create the world's only secure NFT with our technology." - CEO Niko Kipouros. We are witnessing the next chapter in art history with NFTs- Beeple sold a digital work for nearly USD 70 million. Cryptopunks, initially generated for free, are now worth millions. Experienced art & technology specialist 4ARTechnologies is now expanding its patented all-in-one solution for the highly complex NFT landscape. The technology has already brought a revolution for security, efficiency and transparency to the global art industry since 2019 and already accompanies challenging projects with leading institutions such as Munich RE, Ergo Insurance, AON and hasenkamp. With the new expansion, the company offers the safest and easiest entry into the world of NFTs for any of the more than 25 million creating art players worldwi

Bullfinch AG: Bullfinch AG and Aquila Capital launch Joint Investment Vehicle for energy-efficient assets4.5.2021 16:22:12 CEST | Press release

(Frankfurt, Germany): Aquila Capital and bullfinch are pleased to announce the launch of a strategic joint investment vehicle intended to invest in energy efficiency assets across Europe. By combining Aquila Capital’s leading investment experience in real assets and renewable energy, with bullfinch’s unique expertise in decentralized renewable projects and next-gen technology platform, the partnership intends to make an immediate impact in the renewable investment landscape. With more than EUR 25 trillion to be invested in upgrading real estate assets across Europe to achieve climate goals, decentralized green infrastructure projects play an increasingly critical role in fighting climate change. The joint investment vehicle aims to become a relevant pure player in energy efficiency, targeting an investment of more than EUR 200 million in the next two years. Aquila and bullfinch’s initiative will support the fast expansion of digital smart metering through financing, asset acquisition,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom